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Abstract 
Background: Impaired growth is a well-known complication in celiac disease, but factors 
associated with it are poorly known. We investigated this issue in a large cohort of children.  
Methods: Altogether 530 children with biopsy-proven celiac disease were included. The 
participants were divided into two groups on the basis of the presence (n=182) or absence (n=348) 
of growth disturbance at diagnosis. Histological, serological and clinical characteristics were 
compared between children with growth failure and those with normal growth. Further, patients 
with growth failure as the sole clinical presentation were compared to those with poor growth and 
concomitant other symptoms. 
Results: Children with growth failure were younger (p<0.001) and had lower hemoglobin 
(p=0.016) and higher celiac antibody (p<0.001) and thyroid-stimulating hormone values (p=0.013) 
than those with normal growth. Significantly associated with growth failure at celiac disease 
diagnosis were age <3 years (OR 4.3 (95% CI 2.5-7.5) vs older age), diagnosis before the year 2000 
and in 2000-09 (OR 3.1 (1.8-5.4) and OR 1.8 (1.1-2.8) vs diagnosis in 2010-2013), presence of total 
and subtotal villous atrophy (OR 4.2 (2.5-7.0) and OR 2.0 (1.3-3.2) vs partial atrophy), severe 
symptoms (OR 3.4 (1.8-6.7) vs mild symptoms) and vomiting (OR 3.1 (1.5-6.3). The presence of 
abdominal pain reduced the risk (OR 0.5 (0.3-0.7)), while there was no effect of gender, diarrhea, 
constipation, other chronic diseases and celiac disease in the family. Children evincing poor growth 
as the sole clinical presentation were older (p<0.001) and had higher hemoglobin (P<0.001) and 
total iron (p=0.010) values and lower TG2ab values (p=0.009) than those with growth disturbance 
and other symptoms. 
Conclusions: In particular young age and severe clinical and histological presentation were 
associated with growth disturbance at celiac disease diagnosis. Children with only poor growth are 
markedly different from those with other concomitant symptoms, suggesting different pathogenic 
mechanisms. 
Keywords: Celiac disease, Children, Growth failure 
Background 
Population-based screening studies have revealed celiac disease to be a very common health 
problem with a true prevalence of up to 3% in children.1 Besides the classical gastrointestinal 
symptoms, diarrhea and malabsorption, the condition may present with various extraintestinal 
manifestations.2 A frequent, and sometimes the only clinical presentation is impaired growth.3, 4 
Despite being a long-recognized sign of the disease the pathophysiology and factors accompanying 
growth failure in celiac disease remain somewhat obscure. Traditionally the disorder has been 
attributed to severe histological damage leading to malabsorption of essential nutrients, but the 
actual evidence for this is scant.5 Other proposed mechanisms are for example abnormalities in the 
growth hormone/insulin-like growth factor-1 axis6, 7, 8 and increased prevalence of anti-pituitary 
antibodies.9 Regardless of the cause, after the commencement of a gluten-free diet significant catch-
up growth usually follows.10 However, in particular in those diagnosed in later childhood this may 
remain incomplete, leading possibly to reduced adult height,10 though this aspect remains 
controversial.11, 12 The heterogeneous clinical picture of celiac disease makes it difficult to 
recognize and predisposes to long diagnostic delay,13 further increasing the risk of permanent 
growth failure. In order to prevent this complication it would be important to better understand the 
factors associated with poor growth in celiac disease.  
In Finland celiac disease is common, and there have been nationwide guidelines for its diagnosis 
and treatment since the end of the 1990s.14 A major aim of the regularly updated guidelines is early 
diagnosis and subsequent prevention of the possible severe complications, including poor growth in 
childhood. We here investigated the prevalence and associated factors in growth disturbance in 
pediatric celiac disease in the era of the modern diagnostic approach. 
Methods 
Patients and data collection 
The study was conducted at the Tampere Center for Child Health Research, University of Tampere 
and Tampere University Hospital. The study cohort comprised 530 children (age under 16 years at 
diagnosis) with biopsy-proven celiac disease collected in our regularly updated pediatric research 
database. The patient information was either updated prospectively or collected from the medical 
records and, if incomplete, later supplemented with personal or parents’ interviews by a study nurse 
with expertise in celiac disease. The following information was gathered from all study subjects: 
demographic and anthropometric data, year of the celiac disease diagnosis, clinical presentation at 
diagnosis, values of serum celiac disease-specific antibodies and various laboratory parameters, 
severity of small-bowel mucosal damage and presence of either known celiac disease-associated or 
other concomitant chronic disease (e.g. type 1 diabetes mellitus, autoimmune thyroidal disease, 
asthma, allergies) and celiac disease in the family. After the analyses the children were divided into 
subjects with poor growth and those with normal growth prior to the celiac disease diagnosis (see 
below in detail). 
Clinical symptoms 
The severity of the clinical presentation at celiac disease diagnosis was further classified into four 
categories as follows: no symptoms (asymptomatic screen-detected subjects), mild symptoms 
(occasionally disturbing gastrointestinal or extraintestinal symptoms), moderate symptoms 
(multiple or more disturbing or frequent symptoms) and severe symptoms (symptoms seriously 
disturbing normal life; e.g. continuous symptoms or night awakenings due to the symptoms). 
Gastrointestinal symptoms were sub-categorized into diarrhea, abdominal pain, constipation and 
vomiting.  
Serology and laboratory parameters 
In our hospital the serum transglutaminase 2 (TG2ab) antibodies are measured using automatized 
human recombinant-based EliA assay (Phadia AB, Uppsala, Sweden). A TG2ab value of 7 U/l or 
higher is considered positive and the maximum reported value is 120 U/l. Serum endomysial 
antibodies (EmA) are measured in our research center by an indirect immunofluorescence-based in-
house method using human umbilical cord as substrate.15 An EmA dilution of 1:≥5 is considered 
positive and positive sera are further diluted from 1:50 to 1:4000. 
The following laboratory values were collected from each child at diagnosis when available: blood 
hemoglobin (g/l), serum total iron (µmol/l), the mean corpuscular volume (MCV) (fl), serum 
alkaline phosphatase (U/l), serum alanine aminotransferase (ALT) (U/l), serum albumin (g/l), serum 
thyroid-stimulating hormone (TSH) (mU/l) and serum thyroxin (pmol/l). Anemia at diagnosis was 
defined as a blood hemoglobin value lower than that of the age- and gender-specific reference in the 
local hospital laboratory. 
Small-bowel mucosal morphology 
In our clinical practice a minimum of four duodenal samples are taken upon upper gastrointestinal 
endoscopy in all cases of celiac disease suspicion. The biopsies are passed to the pathology unit, 
where they are processed and analyzed. Only correctly oriented specimens are accepted for further 
microscopic analyses.16 The severity of small-bowel mucosal villous atrophy here was categorized 
based on the hospital pathologist´s original grading into partial (PVA), subtotal (SVA) and total 
villous atrophy (TVA). These correspond approximately to Marsh-Oberhuber grades IIIa, IIIb and 
IIIc.  
Growth parameters 
Height-for-age was expressed in standard deviation (SD) units, which compare the height of a child 
to the average height of Finnish children of the same age.17 Poor growth was defined as an 
abnormal deceleration of growth development compared with age- and gender-specific reference 
values or growth below the of expected target height based on the mean of parental heights.18 The 
expected growth rate was considered abnormally low if the current height differed from the 
expected more than -2.3 SD. If the parental heights were not known, the child’s height was allowed 
to differ a maximum of -2.7 SD from the age- and sex-based reference.17 The weight of the children 
was expressed as weight-for-height percentage, as age- and gender-matched SD units and as body 
mass index (BMI, kg/m2).  
Ethical aspects 
Collection of the medical records and patient interviews were approved by the Department of 
Pediatrics, Tampere University Hospital and by the Ethics Committee of the Pirkanmaa Hospital 
District, Tampere, Finland. Written informed consent was obtained from all patients and/or their 
parents participating in the personal interviews. 
Statistical analysis 
Statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) 
statistical software (SPSS Inc., Chicago, IL, USA). In Tables 1, 2 and 5 the data are expressed 
either in medians with upper and lower quartiles (Q1, Q3) or as percentages and differences 
between the growth failure and normal growth groups were compared with Mann-Whitney U test or 
Chi square test. In Tables 3 and 4 the relative risk of growth failure is expressed using odds ratios 
with 95% confidence intervals. A P value < 0.05 was considered statistically significant.  
Results 
Altogether 182 (34%) children presented with disturbed growth and 348 (66%) with normal growth 
at celiac diagnosis. Children with poor growth were significantly younger and had by definition 
lower median height but also lower weight parameters compared with those with normal growth 
(Table 1). There was also a trend towards later onset of menarche in girls with growth failure, but 
this was not significant (Table 1). 
Serum EmA and TG2ab values were significantly higher in the growth failure group than in the 
normal growth group at diagnosis (Table 1). Further, median hemoglobin was significantly lower 
and ALAT and TSH higher in children with poor growth. TSH was above the reference in 4 
children with growth disturbance and in 2 with normal growth; however, none of these 6 had TSH 
values >10 mU/l or other clinical signs of hypothyroidism such as fatigue, increasing weight or 
weakness. No differences in thyroxin values or other laboratory parameters were observed between 
the groups (Table 1). Previously diagnosed concomitant thyroid disease under treatment was noted 
in 7 (4.1%) children with poor growth and 6 (1.7%) with normal growth (p=0.102). 
Among the demographic and clinical characteristics significantly associated with growth 
disturbance at celiac disease diagnosis was age below three years compared with older age and 
celiac disease diagnosis before the year 2010 compared with the later era (Table 2). There was no 
association between growth failure and gender, presence of any other concomitant chronic disease 
or presence of celiac disease in the family (Table 2). 
A significant association was seen between abnormal growth and the presence of subtotal and total 
small-bowel mucosal villous atrophy (Table 3). Of symptoms overall the presence of in general 
severe symptoms and of specific gastrointestinal symptoms vomiting increased the risk of poor 
growth. In contrast, abdominal pain reduced the risk, whereas the presence of diarrhea, constipation 
and anemia had no effect (Table 3). 
In a separate analysis among the 182 children with growth failure this was the sole clinical 
presentation of celiac disease in 46 (25%) subjects at diagnosis, while the remaining 136 (75%) also 
had other clinical symptoms (Table 4). Children with poor growth as the sole manifestation were 
significantly older and had higher hemoglobin, MCV and total iron values and lower TG2ab values 
than those with other concomitant symptoms, while there were no significant differences between 
the groups in the other study variables (Table 4).   
Discussion 
The present study demonstrated that children with poor growth at celiac disease diagnosis are 
significantly younger and have more severe disease in terms of symptoms, serology and histological 
damage compared with those with normal growth. It was also shown that the risk of growth failure 
has decreased during the past few decades, and that children with growth failure as the sole 
presentation are markedly different from those with concomitant other symptoms. 
The association between histology and growth was demonstrated by the more frequent observation 
of poor growth in children with subtotal or total villous atrophy compared with those with partial 
atrophy. Although a seemingly logical finding, there is a surprising scarcity of studies touching 
upon this issue, and the few conducted have shown no clear relationship.19, 21, 22 This discrepancy 
between the present and earlier results might be explained by the smaller numbers of patients in 
previous studies and variable definitions of growth failure. Weizman and colleagues19 also 
speculated that the extent of mucosal damage might be more related to poor growth in celiac 
disease than the degree of atrophy; this is however, contradicted by evidence that the extent of 
enteropathy does correlate with clinical presentation.22 Our findings support the role of villous 
atrophy and malabsorption of essential nutrients as an important cause of decreased growth in celiac 
disease. In accord with this was the observation of lower weight and hemoglobin values in the 
growth failure group.  
Here children with poor growth had significantly higher celiac antibody levels at diagnosis than 
those with normal growth. Previously Bingley and colleagues23 have shown EmA-positive children 
to be shorter and lighter than corresponding seronegative non-celiac children. To our knowledge, 
however, the difference in serology noted here in children with celiac disease has not previously 
been reported before. The finding is in accord with the previously shown association between 
higher antibody levels and more severe histological and clinical presentation.20, 24, 25 The correlation 
between serology and poor growth might thus in fact be a result of more severe mucosal damage, 
but it is also possible that the antibodies have a direct role in the disease pathogenesis.26 
The presence of growth failure was also associated with generally more severe gastrointestinal 
symptoms. Of specific symptoms vomiting increased the risk, while diarrhea, somewhat 
unexpectedly, did not. In contrast, the presence of the “non-classical” symptom abdominal pain in 
fact reduced the risk. Severity of gastrointestinal symptoms has previously been linked with more 
advanced villous atrophy in some studies19, 24 but not in others.27, 28 Interestingly, adult celiac 
disease patients with diarrhea were recently shown to have less severe villous atrophy than those 
with anemia,29 demonstrating the complicated relationship between clinical and histological 
presentation. It is also possible to have growth-disturbing protein-losing enteropathy without 
diarrhea.30 The protective effect of abdominal pain might be explained for example by less severe 
villous atrophy in these subjects. Obviously more studies are needed to decipher the mechanisms 
behind the multifaceted clinical picture in celiac disease. 
Children with poor growth were almost two years younger than those with normal growth, and at 
particular risk were those below three years at diagnosis. Similar results have previously been 
reported from Sweden.31 These findings suggest that the rapid growth during infancy is particularly 
vulnerable to malabsorption caused by untreated celiac disease. Conversely, it is possible that 
toddlers with poor growth as a presenting symptom are diagnosed earlier since they are regularly 
followed in child welfare clinics. Interestingly, children with growth failure as the sole presentation 
were significantly older than those with concomitant other symptoms. There could be different 
pathophysiological mechanisms present, and it has indeed been speculated that poor growth in 
children with classical symptoms is caused by malabsorption and in those with atypical presentation 
by abnormalities in the growth hormone-insulin-like growth factor axis.6, 7, 8, 32 Also, as presumed in 
Crohn’s disease33, mucosal inflammation may directly contribute to abnormal growth. Because of 
the increased risk of growth hormone deficiency, there should be low threshold for endocrinological 
evaluation in children with no significant catch-up growth after one year on a gluten-free diet. 
Interestingly, the TSH values here were higher in the growth failure group. Children with celiac 
disease are known to be at increased risk of autoimmune thyroid diseases.34 This notwithstanding, 
four children with growth failure had TSH values above the reference and none of them had other 
hypothyreosis symptoms or values usually required for such a diagnosis.35 It is still possible that 
subclinical hypothyreosis had an exacerbating effect on the poor growth, but currently it remains 
controversial whether these children would benefit from hormone replacement therapy.36 In any 
case, it is important to remember the possibility of associated thyroid disease in poorly growing 
children with celiac disease. 
The finding that risk of growth failure was decreased over time is in line with other recent reports4, 
31, 37 and very likely reflects earlier diagnosis due to increased awareness and improved diagnostic 
tools. We found a higher prevalence of poor growth than previously reported by Savilahti and 
colleagues4 but lower than that reported by group under Rashid.38 These discrepancies might be 
explained by differences in definition, as growth failure has often been defined as a height below -2 
SD compared with the reference population (“short stature”), 4 whereas we defined it as either 
height below the expected target or abnormal deflection of the growth. The latter method has 
proved effective and may allow indentification children with celiac disease earlier and thus reduce 
the risk of permanent growth failure.19, 39 In contrast, short stature as such is often only a normal 
variant and thus not a particularly reliable marker for true growth abnormality.40 
The strengths of this study were its large size and well-defined celiac disease diagnoses. We also 
had a wide range of clinically relevant data on each patient. Nevertheless, in particular laboratory 
values were lacking in a substantial part of the study subjects. Another limitation was that, although 
proved appropriate, the definition of growth failure used here might limit generalization of the 
results. Finally, since growth hormone metabolism or other endocrinological factors possibly 
implicated were not investigated here, we cannot verify the mechanisms underlying poor growth, 
this being an issue for future studies. 
Conclusions 
To conclude, our results demonstrate that growth failure in symptomatic children with celiac 
disease is associated in particular with young age and severe presentation at diagnosis. Differences 
between children having poor growth as the sole clinical presentation and those with concomitant 
other symptoms indicate that there are different underlying mechanisms.  
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Table 1. Baseline characteristics in 530 children with or without growth failure before celiac 
disease diagnosis. 
  Growth failure n=182 
 Normal growth 
n=348 
 
 n* Median (Q1, Q3) n* Median (Q1, Q3) P value 
Age at diagnosis, yr 182 6.3 (2.5, 11.7) 348 8.0 (5.0, 12.0) <0.001 
Age of menarche, yr 23 13.0 (12.0, 13.0) 45 12.0 (12.0, 13.0) 0.146 
Height, SD 45 -0.5 (-1.2, 0.4) 134 0.2 (-0.5, 0.9) 0.004 
Weight, SD 34 -1.1 (-1.9, -0.2) 114 -0.3 (-0.9, 0.6) 0.003 
Weight/height percentage 65 -9.0 (-15.0, -1.0) 163 0.1 (-8.0, 9.0) <0.001 
Body mass index, kg/m2 68 15.7 (14.3, 16.6) 155 16.6 (15.1, 19.2) <0.001 
EmA, titer 81 500 (200, 2000) 205 200 (100, 1000) <0.001 
TG2ab, U/l† 98 120.0 (71.3, 120.0) 253 120.0 (39.0, 120.0) 0.035 
Hemoglobin, g/l 129 122 (115, 128) 248 126 (115, 133) 0.016 
MCV, fl 96 81 (75, 83) 207 81 (76, 83) 0.662 
Alkaline phosphatase, U/l 42 309 (148, 511) 79 231 (184, 322) 0.180 
Total iron, µmol/l 33 10.0 (6.6, 15.0) 58 12.5 (9.3, 17.8) 0.304 
Albumin, g/l 18 37 (34, 41) 50 39 (37, 41) 0.252 
TSH, mU/l 43 2.8 (2.2, 3.7) 58 2.4 (1.6, 3.1) 0.013 
Thyroxin, pmol/l 31 14.4 (12.6, 16.9) 25 14.8 (12.9, 16.3) 0.817 
Q1, Q3 = lower and upper quartiles; SD = standard deviation; EmA = endomysial antibodies; 
TG2ab = transglutaminase 2 antibodies; MCV = mean corpuscular volume; TSH = thyroid 
stimulating hormone 
*Data available 
†Upper limit of the assay 120.0 U/l 
 
  
Table 2.  Association between clinical characteristics and growth disturbance at diagnosis in 530 
children with celiac disease 
 n* Growth failure, % Odds ratio  95% CI P value 
Gender      
Boys 194 33.5 1   
Girls 336 34.8 1.06 0.73 - 1.54 0.759 
Age at diagnosis, years 
<3 74 66.2 4.32 2.49 - 7.48 <0.001 
3-7 203 26.6 0.80 0.53 - 1.20 0.281 
8-17 253 31.2 1   
Year of diagnosis 
<2000 114 48.2 3.11 1.82 - 5.35 <0.001 
2000-09 277 34.3 1.75 1.10 - 2.78 0.019 
2010-13 139 23.0 1   
Type 1 diabetes mellitus 
No 475 33.7 1   
Yes 41 24.4 0.64 0.30 - 1.33 0.228 
Thyroid disease      
No 502 32 1   
Yes 13 54 2.45 0.81 - 7.40 0.113 
Asthma 
No 474 32.9 1   
Yes 42 33.3 1.02 0.52 - 1.99 0.956 
History of allergy 
No 393 34.9 1   
Yes 125 28.0 0.73 0.47 - 1.13 0.157 
Other concomitant chronic disease† 
No 202 29.7 1   
Yes 315 35.6 1.31 0.89 - 1.91 0.169 
First-degree relative with celiac disease 
No 157 35.7 1   
Yes 140 26.4 0.65 0.39 - 1.07 0.087 
*Data available 
†E.g. epilepsy, rheumatoid arthritis, psychiatric disorder, inflammatory bowel disease, congenital 
heart disease, immune deficiency 
 
   
Table 3.  Association between histologic and symptomatic presentation and growth disturbance at 
diagnosis in 530 children with celiac disease 
 n* Growth failure, % Odds ratio 95% CI P value 
Degree of small-bowel mucosal villous atrophy 
Partial 174 20.7 1   
Subtotal 194 34.5 2.02 1.26 - 3.24 0.003 
Total 126 52.4 4.22 2.54 - 7.00 <0.001 
Severity of symptoms†  
Mild 258 28.7 1   
Moderate 107 35.5 1.37 0.85 - 2.21 0.198 
Severe 43 58.1 3.45 1.78 - 6.70 <0.001 
Asymptomatic 121 37.2 1.47 0.93 - 2.33 0.097 
Diarrhea 
No 319 32.3 1   
Yes 181 37.6 1.26 0.86 - 1.85 0.232 
Abdominal pain 
No 267 42.7 1   
Yes 230 25.7 0.46 0.32 - 0.68 <0.001 
Constipation 
No 425 35.8 1   
Yes 72 26.4 0.64 0.37 - 1.13 0.124 
Vomiting 
No 466 32.4 1   
Yes 32 59.4 3.05 1.47 - 6.34 0.003 
Anemia      
No 420 32.4 1   
Yes 91 37.4 1.25 0.78 - 2.00 0.361 
*Data available 
†Growth failure was not considered as a symptom here 
Table 4. Comparison of baseline data between celiac children with poor growth as sole clinical 
presentation and those with other concomitant symptoms. 
 n* 
Poor growth as 
only symptom 
n=46 
n* 
Poor growth with 
other symptoms 
n=136  
P value 
Age at dg, median, yr 46 11.5 (7.4, 13.1) 136 5.0 (2.0, 10.0) <0.001 
Girls, % 46 54 136 67 0.104 
Anemia, % 40 15 130 22 0.085 
Degree of villous atrophy, %   0.449 
Partial 10 23 26 21  
Subtotal 14 32 53 42  
Total 20 45 46 37  
Body mass index, kg/m2 24 15.5 (14.3, 17.0) 44 15.8 (14.3, 16.5) 0.847 
Hemoglobin, g/l 28 128 (123, 135) 101 120 (110, 127) <0.001 
MCV, fl 23 82 (78, 85) 73 79 (74, 83) 0.039 
Alkaline phosphatase 10 284 (119, 640) 32 320 (148, 511) 0.859 
Total iron, µmol/l 8 19.5 (9.9, 34.2) 25 7.5 (5.6, 14.2) 0.010 
TSH, mU/l 12 3.1 (1.8, 3.8) 31 2.7 (2.0, 3.6) 0.684 
Thyroxin, pmol/l 8 15.9 (14.3, 18.1) 23 14.2 (12.5, 16.4) 0.298 
EmA, titer 26 500 (200, 1250) 81 1000 (200, 4000) 0.516 
TG2ab, U/l 31 120 (30, 120) 67 120 (95, 120) 0.009 
SD = standard deviation; MCV = mean corpuscular volume; TSH = thyroid stimulating 
hormone; EmA = endomysial antibodies; TG2ab = transglutaminase 2 antibodies 
*Data available 
 
 
